相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer
Jennifer M. Brannan et al.
CLINICAL CANCER RESEARCH (2009)
Distinct roles for Crk adaptor isoforms in actin reorganization induced by extracellular signals
Susumu Antoku et al.
JOURNAL OF CELL SCIENCE (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
Kimio Yonesaka et al.
CLINICAL CANCER RESEARCH (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
Hendrik Fischer et al.
MOLECULAR CANCER THERAPEUTICS (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS
Udayan Guha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Signaling networks assembled by oncogenic EGFR and c-Met
Ailan Guo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets
Uwe Rix et al.
BLOOD (2007)
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Jayne M. Stommel et al.
SCIENCE (2007)
The Btk tyrosine kinase is a major target of the Bcr-Abi inhibitor dasatinib
Oliver Hantschel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
High-throughput phosphotyrosine profiling using SH2 domains
Kazuya Machida et al.
MOLECULAR CELL (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells totreatment with gefitinib
Floriana Morgillo et al.
CLINICAL CANCER RESEARCH (2007)
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts
Neelu Puri et al.
CANCER RESEARCH (2007)
Proteomics analysis in lung cancer: Challenges and opportunities
Takefumi Kikuchi et al.
RESPIROLOGY (2007)
Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors
Justin M. Balko et al.
BMC GENOMICS (2006)
Charging it up: global analysis of protein phosphorylation
Jason Ptacek et al.
TRENDS IN GENETICS (2006)
The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease
Justin Lamb et al.
SCIENCE (2006)
Quantitative multiplexed profiling of cellular signaling networks using phosphotyrosine-specific DNA-tagged SH2 domains
Kevin Dierck et al.
NATURE METHODS (2006)
Phosphoproteomic approaches to elucidate cellular signaling networks
Katrin Schmezle et al.
CURRENT OPINION IN BIOTECHNOLOGY (2006)
The human and mouse complement of SH2 domain proteins -: Establishing the boundaries of phosphotyrosine signaling
Bernard A. Liu et al.
MOLECULAR CELL (2006)
Requirement of Nck adaptors for actin dynamics and cell migration stimulated by platelet-derived growth factor B
G. M. Rivera et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival
Lanxi Song et al.
CANCER RESEARCH (2006)
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients
RL Yauch et al.
CLINICAL CANCER RESEARCH (2005)
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition
S Thomson et al.
CANCER RESEARCH (2005)
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells
FM Johnson et al.
CLINICAL CANCER RESEARCH (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
The SH2 domain: versatile signaling module and pharmaceutical target
K Machida et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)-endogenous negative regulators of Src-family protein kinases
YP Chong et al.
GROWTH FACTORS (2005)
Specificity in signal transduction: From phosphotyrosine-SH2 domain interactions to complex cellular systems
T Pawson
CELL (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Statistical significance for genomewide studies
JD Storey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Profiling the global tyrosine phosphorylation state by Src homology 2 domain binding
P Nollau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
